Biodesix, Inc. Common Stock
BDSXStock
$19.96+243.14%52W
Market Cap$206.70M
P/E—
Div yield—
Beta0.57
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)242.89%
Price vs S&P 500 (4W)36.39%
VGM Score63.99
Market Capitalization$206.70M
Earnings Surprise History
Q1 26-0.81est. -1.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.18
4.18
4.18
4.18
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BDSXBiodesix, Inc. Common Stock | D | B | A | $19.96 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
About
Biodesix is a lung-focused diagnostic company that provides blood-based testing services for lung cancer and COVID-19. The company generates revenue through two primary channels: direct diagnostic testing services and partnerships with biopharmaceutical companies for clinical trial diagnostics and companion diagnostic development. This dual-revenue model positions Biodesix at the intersection of clinical diagnostics and drug development, creating diverse market opportunities.